Last reviewed · How we verify
NCT04378712
Hydrogen/Oxygen Mixed Gas Inhalation for Coronavirus Disease 2019 (COVID-19)
NA trial testing Hydrogen Oxygen Generator with Nebulizer in Covid-19 in 90 participants. Completed in 23 March 2020.
23 March 2020
Quick facts
| Lead sponsor | Guangzhou Institute of Respiratory Disease |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 90 |
| Start date | 21 January 2020 |
| Primary completion | 23 March 2020 |
| Estimated completion | 23 March 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- Hydrogen Oxygen Generator with Nebulizer
- Standard-of-care — full drug profile →
Conditions studied
- Covid-19 — all drugs for Covid-19 →
- Hydrogen/Oxygen Mixed Gas — all drugs for Hydrogen/Oxygen Mixed Gas →
- Dyspnea — all drugs for Dyspnea →
Sponsor
Guangzhou Institute of Respiratory Disease
Who can join
Adults 18 to 75, any sex, with Covid-19 or Hydrogen/Oxygen Mixed Gas. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This was a randomized, multi-center, open-label clinical trial. Eligible patients were recruited from seven hospitals in China. On the basis of standard-of-care, patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) until discharge. Patients in control group received standard-of-care (consisting of oxygen therapy) alone until discharge.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Hydrogen/oxygen mixed gas inhalation improves disease severity and dyspnea in patients with Coronavirus disease 2019 in a recent multicenter, open-label clinical trial.
Guan WJ, Wei CH, Chen AL, Sun XC, et al · · 2020 · cited 70× · PMID 32642277 · DOI 10.21037/jtd-2020-057 -
COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials.
Chakraborty R, Parvez S. · · 2020 · cited 35× · PMID 32739342 · DOI 10.1016/j.bcp.2020.114184 -
COVID-19 associated complications and potential therapeutic targets.
Monpara JD, Sodha SJ, Gupta PK. · · 2020 · cited 21× · PMID 32926918 · DOI 10.1016/j.ejphar.2020.173548 -
Molecular Hydrogen Therapy: Mechanisms, Delivery Methods, Preventive, and Therapeutic Application.
Jin J, Yue L, Du M, Geng F, et al · · 2025 · cited 16× · PMID 40297245 · DOI 10.1002/mco2.70194 -
Neonatal asphyxia as an inflammatory disease: Reactive oxygen species and cytokines.
Okazaki K, Nakamura S, Koyano K, Konishi Y, et al · · 2023 · cited 16× · PMID 36776908 · DOI 10.3389/fped.2023.1070743 -
Molecular Hydrogen: A Promising Adjunctive Strategy for the Treatment of the COVID-19.
Li Y, Wang Z, Lian N, Wang Y, et al · · 2021 · cited 7× · PMID 34746162 · DOI 10.3389/fmed.2021.671215
Verify or expand the search:
- PubMed search for NCT04378712
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Hydrogen Oxygen Generator with Nebulizer
Trials testing the same drug.
- NCT05282836 — Early Hydrogen-Oxygen Gas Mixture Inhalation in Patients With Aneurysmal Subarachnoid Hemorrhage (HOMA) · NA · unknown
Other recruiting trials for Covid-19
Currently open trials in the same condition.
- NCT05943743 — Hiccups and Obstacles Of E-Learning Among Medical Sudents · recruiting
- NCT04466683 — Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia · Phase 2 · active not recruiting
- NCT04433364 — COPE - COVID-19 in Pregnancy and Early Childhood · active not recruiting
- NCT04568148 — COVID-19 Biorepository · active not recruiting
- NCT04360538 — Long Term Outcomes of Patients With COVID-19 · active not recruiting
Other Guangzhou Institute of Respiratory Disease trials
Trials by the same sponsor.
- NCT07092137 — Nano-crystalline Megestrol Acetate for Anorexia-Cachexia Syndrome in Advanced Lung Cancer · Phase 2 · not yet recruiting
- NCT06909383 — Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Can · Phase 2 · not yet recruiting
- NCT07005999 — Interventional Ablation for Early-stage Lung Cancer · active not recruiting
- NCT06739928 — Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC · Phase 2 · recruiting
- NCT06715956 — Observational Study of Sputum Inflammation Phenotypes and Clinical Outcomes in Non-Cystic Fibrosis Bronchiectasis · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04378712 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangzhou Institute of Respiratory Disease
- Last refreshed: 15 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04378712.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing